Hoechst Marion Roussel Hypertension Research Clinical Fellowship Award 1999

Abstract

HomeHypertensionVol. 35, No. 1Hoechst Marion Roussel Hypertension Research Clinical Fellowship Award 1999 Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUBHoechst Marion Roussel Hypertension Research Clinical Fellowship Award 1999 Originally published1 Jan 2000https://doi.org/10.1161/01.HYP.35.1.524Hypertension. 2000;35:524–535Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: September 8, 2018: Previous Version of Record The purpose of this program and research award is to stimulate physicians-in-training to pursue a career in clinical research in hypertension. The research fellow must be conducting work in which he is the major senior investigator in any area of his choice, including clinical or laboratory aspects of the hypertensive diseases. The fellow’s work would be supervised by the director of the research training program (the mentor), but the conduct of the investigation is primarily by the research fellow. The winning presentation receives $3000 and the fellow’s mentor receives $25 000 to support the clinical investigative training of a research fellow the following year.Dr David Geller received his MD and PhD degrees from New York University School of Medicine. He performed his graduate work in the laboratory of Dr G. Nigel Godson, studying mechanisms of transcriptional regulation in Escherichia coli. He completed his internship and residency in Internal Medicine at Yale New Haven Hospital in 1996 and then undertook a fellowship in Nephrology at Yale University. During his fellowship, he has worked in the laboratory of Dr Richard Lifton, with an interest in understanding genetic factors which underlie hypertension. With Dr Lifton, Dr Geller has identified a novel mendelian form of human hypertension caused by an activating mutation in the mineralocorticoid receptor. The mutation allows for activation of the receptor by novel steroids ligands, thus leading to sodium retention and severe early-onset hypertension in patients carrying this mutation. The findings add to our understanding of the role of aldosterone in human hypertension and cardiovascular physiology. Furthermore, the insight gained into steroid hormone receptor biology will aid in the design of receptor agonists and antagonists as well.Previous Recipients of the Hoechst Marion Roussel Hypertension Research Clinical Fellowship Award1998 Martin Matsubara, MD, University of Virginia, Mentor: Coleen McNamara 1997 W. Reid Litchfield, MD, Harvard Medical School/Brigham and Women’s Hospital, Mentor: Robert G. Dluhy 1996 David B. Simon, MD, Yale University School of Medicine, Mentor: Richard Lifton 1995 Joni H. Hansson, MD, Yale University School of Medicine, Mentor: Richard Lifton 1994 John Krege, MD, University of North Carolina, Mentor: Oliver Smithies 1993 Luis A. Juncos, MD, Henry Ford Hospital, Mentors: Sadayoski Ito and Oscar A. Carretero 1992 Amy L. Tucker, MD, University of Virginia, Mentor: Kevin R. Lynch 1991 Elizabeth Gilbert D’Angelo, MD, University of Virginia, Mentor: Christopher M. Rembold 1990 Bruno Escalante, MD, New York Medical College, Mentor: John C. McGiff 1989 Allen Everett, MD, University of Virginia, Mentor: Ariel Gomez 1988 Allen J. Naftilan, MD, Harvard Medical School/Brigham and Women’s Hospital, Mentor: Victor J. Dzau 1987 Christopher M. Rembold, MD, University of Virginia, Mentor: Carlos R. Ayers 1986 Judith E. Kalinejak, MD, PhD, Stanford Medical Center, Mentor: Andrew J. Perlman 1985 Gail K. Adler, MD, PhD, Harvard Medical School/Peter Bent Brigham Hospital, Mentor: Gordon H. Williams 1984 Christine Seidman, MBBS, Harvard Medical School/Massachusetts General Hospital, Mentor: Robert M. GrahamIrvine Page–Alva Bradley Lifetime Achievement Award 1999The American Heart Association Council for High Blood Pressure Research is proud to present the 1999 Irvine Page–Alva Bradley Lifetime Achievement Award to Myron H. Weinberger, MD, for his outstanding contributions to our understanding of the mechanisms and therapy of human hypertension.Dr Weinberger is Professor of Medicine and Director of the Hypertension Research Center at the Indiana University School of Medicine, where he earned his Bachelor of Science in zoology in 1959 and his medical degree in 1963.In addition to his outstanding research achievements, Dr Weinberger also provided exemplary leadership as an American Heart Association volunteer and on the Indiana Affiliate Board of Directors. He also played an integral role on the Council for High Blood Pressure Research, the Scientific Sessions Program Committee, the Cardiovascular A Research Study Committee, and many other committees.He has been active in several other organizations, including the American Association of Clinical Endocrinologists, American Society of Hypertension, and the American Society for Clinical Pharmacology and Therapeutics. Additionally, he has been a member of many editorial boards and had published more than 300 papers and many prestigious journals and books.Among the many achievements during his illustrious career, Dr Weinberger received the prestigious Robert Tigerstedt Award from the American Society of Hypertension in 1996.For these−and many other achievements during his distinguished career−the Council for High Blood Pressure Research honors Myron H. Weinberger as the 1999 Irvine Page–Alva Bradley Lifetime Achievement Award recipient.Past Recipients of the Lifetime Achievement Award1998 David H.P. Streetan, Dphil 1997 Norman M. Kaplan, MD 1996 Edward George Biglieri, MD 1995 William Francis Ganong, MD 1994 Stevo Julius, MD, DSc 1993 Edward D. Frohlich, MD 1992 Ray W. Gifford, Jr, MD 1991 Harriet P. Dustan, MD 1990 Aram V. Chobanian, MDNovartis Award for Hypertension Research 1999In recognition of outstanding contributions made in hypertension research, the Novartis (formerly CIBA) Award has been presented at the annual meeting of the Council for High Blood Pressure Research since 1975. The Novartis Award continues the tradition of the CIBA Award and the Stouffer Prize, first awarded to Ernst Klenk, MD, and Harry Goldblatt, MD, in 1966. In 1999, the Novartis Award was presented to Richard P. Lifton, MD, PhD.Dr Richard P. Lifton received the 1999 Novartis Award for Hypertension Research for his discovery of mutations altering blood pressure in humans. He received his BA from Dartmouth College and the MD and PhD degrees from Stanford University. He did his housestaff training and was Chief Resident in Internal Medicine at Brigham and Women’s Hospital before joining the faculty at Harvard Medical School He later moved to Yale University as an investigator of the Howard Hughes Medical Institute. He is currently Chairman of the Department of Genetics and Professor of Genetics, Internal Medicine, and Molecular Biophysics and Biochemistry at Yale. His work has focused on the molecular genetics of cardiovascular and renal disease. From the study of families with inherited diseases, his laboratory has mapped the chromosomal location of 25 human disease genes and has identified the genes and mutations causing 15 of these diseases. His primary interest has been identification of mutations that alter blood pressure in humans, studying families with rare mendelian forms of high and low blood pressure in which mutations in single genes impart large effects on blood pressure. To date, his laboratory has discovered mutations in 4 genes that raise blood pressure and 8 genes that lower blood pressure and has mapped two other hypertension genes that have not yet been identified at the molecular level. Hypertensive diseases include glucocorticoid remediable aldosteronism (caused by ectopic expression of aldosterone synthase in adrenal fasciculata), Liddle’s syndrome (caused by mutations in either the β- or γ-subunits of the epithelial sodium channel that result in prolonged half-life of the channel at the cell surface), and pseudohypoaldosteronism type II (mapped to chromosomes 1 and 17 but not yet identified at the molecular level). Hypotensive diseases include pseudohypoaldosteronism type I (the recessive form caused by loss of function mutations in any of the 3 subunits of the epithelial sodium channel and the dominant form caused by loss of function of the mineralocorticoid receptor), Gitelman’s syndrome (caused by loss of function mutation in the thiazide-sensitive Na-Cl cotransported), and Bartter’s syndrome (caused by loss of function mutations in the Na-K-2Cl cotransported, the K+ channel ROMK, and the Cl− channel CLCNKB). It is noteworthy that all of these genes alter blood pressure through a final common pathway, altering net renal salt reabsorption; mutations that increase salt reabsorption raise blood pressure, whereas mutations that impair salt reabsorption lower blood pressure. These findings demonstrate the critical role of the kidney and renal salt homeostasis in the determination of the blood pressure in humans. These studies have defined a final common pathway for determination of blood pressure in humans, explain the molecular basis and physiology of these diseases, and have permitted development of novel genetic screening tests. Moreover, they have identified several novel targets for identification of new or improved antihypertensive diuretic agents that may have clinical utility. Finally, these studies of rare families have motivated the careful examination of the genes whose products mediate or regulate renal salt reabsorption for their potential role in determining blood pressure variation in the general population.Past Recipients of the Novartis Award1998 Masashi Yanagisawa, MD, PhD 1997 Oscar A. Carretero, MD Allen W. Cowley, Jr, PhD Donald D. Heistad, MDPast Recipients of the CIBA Award1996 Robert J. Lefkowitz, MD Oliver Smithies, Dphil 1995 Louis J. Ignarro, PhD Salvador Moncada, MD, PhD, DSc, FRS 1994 Adolfo J. DeBold, OC, PhD, FRSC Ervin G. Erdos, MD 1993 John Paul Rapp, DVM, PhD 1992 Detlev Ganten, MD, PhD 1991 Salomon Z. Langer, MD Andrew P. Somlyo, MD Avril V. Somlyo, PhD 1990 Francis M. Abboud, MD Michael J. Brody, PhD 1989 Edgar Haber, MD 1988 Robert R. Furchgott, PhD Ferid Murad, MD, PhD 1987 Donald J. Reis, MD 1986 Maurice B. Burg, MD John C. McGiff, MD E. Eric Muirhead, MD 1985 Pierre Corvol, MD Tadashi Inagami, PhD Joel Menard, MD 1984 David F. Bohr, MD 1983 David W. Cushman, PhD Sergio Henrique Ferreira, MD, PhD Miguel A. Ondetti, PhD 1982 Kyuzo Aoki, MD Kozo Okamoto, MD Yukio Yamori, MD 1981 Edward D. Freis, MD William B. Kannel, MD 1980 Bjorn U.G. Folkow, MD, PhD Arthur C. Guyton, MD 1979 Karl H. Beyer, Jr, MD James M. Sprague, PhD 1978 Louis Tobian, Jr, MD 1977 John A. Luetscher, MD James F. Tait, FRS Sylvia A.S. Tait, BSc, FRS 1976 Raymond P. Ahlquist, PhD James Q. Black, MD 1975 Lewis K. Dahl, MD James O. Davis, MD Walter Kempner, MDPast Recipients of the Stouffer Prize1972 Vincent P. Dole, MD John W. Gofman, MD Robert S. Gordon, Jr, MD John L. Oncley, MD 1970 Irvine H. Page, MD Sir George Pickering, MD 1969 Jerome W. Conn, MD Jacques Genest, MD Franz Gross, MD John H. Laragh, MD 1968 F. Merlin Bumpus, PhD W. Stanley Peart, MD 1967 John W. Cornforth, MD US von Euler, MD Peter Holtz, MD George J. Popjak, MD 1966 Ernst Klenk, MD Harry Goldblatt, MDHarry Goldblatt Award 1999The Goldblatt Award is presented each year to the author(s) of the paper(s) from last year’s meeting judged by the Publication Committee of the Council for High Blood Pressure Research to represent the most significant new contribution to the understanding of the causes and/or consequences of hypertension. The award is named for the eminent hypertension researcher Dr Harry Goldblatt and is supported by a generous donation to the council from his family. Included with the award is a $1000 honorarium and a commemorative plaque.The 1999 Goldblatt Award was presented to Dr Craig H. Gelband from the Department of Physiology, University of Florida College of Medicine. Dr Gelband is a fellow of the Council for High Blood Pressure Research and has been a member of the council for many years. Dr Gelband’s research interests have concentrated on the study of renal vascular control systems with principal emphasis on alterations of renal vascular K+ and Ca2+ channels in hypertension. His earlier studies revealed that contractile activity, endothelial function membrane potential, K+ currents, and L-type Ca2+ currents in genetic (the spontaneously hypertensive rat or SHR) and nongenetic deoxycorticosterone acetate hypertensive (or DOCA) models of hypertension were altered when compared with their proper controls. The patch-clamp technique, Ca2+ imaging fluorescence, and contractile assays were used to examine the differences in Wistar Kyoto (WKY), Sprague-Dawley (SD), SHR, and DOCA rat renal resistance arterioles and vascular smooth muscle cells dissociated from these vessels. The data showed that renal resistance arterioles from the hypertensive models were more sensitive to the vasoconstrictor agents angiotensin II, potassium chloride, and phenylephrine and showed significant endothelial dysfunction when preconstricted vessels were challenged with acetylcholine. Electrophysiologically, cells dissociated from the SHR and DOCA renal resistance arteriole vessels were more depolarized than the control, which would lead to a greater amount of vasoconstriction in vivo. It was also found that voltage-dependent Kv current was decreased in hypertension, whereas KCa and L-type calcium current was increased in the cells from hypertensive rats. Finally, basal, KCI, and angiotensin II (Ang II)-stimulated intracellular free [Ca2+] was greater in the SHR and DOCA hypertensive cells when compared with control. Theses results suggested that membrane potential, KCa, Kv, and Ca2+ channels were altered in hypertensive rat renal resistance arterioles and may play a role in the regulation of renal blood flow under physiological and pathophysiological conditions.The work presented for the Goldblatt Award represents Dr Gelband’s investigations into the use of antisense gene therapy targeting the renin-angiotensin system in preventing some of the renovascular alteration observed in hypertension. The paper entitled “Angiotensin II Type 1 Receptor Antisense (AT1R-AS) Gene Therapy Prevents Altered Renal Vascular Calcium Homeostasis in Hypertension” showed that delivery of AT1R-AS in neonates prevented the development of hypertension in the SHR for at least 210 days. At this time, untreated SHR renal resistance arterioles showed a significantly enhanced contractile response to KCI and Ang II when compared with the normotensive WKY rat. In addition, L-type Ca2+ current density and Ang II–dependent increases in [Ca2+] were significantly increased in cells dissociated from renal resistance arterioles of the untreated SHR. AT1R-AS treatment prevented all of the above vascular alterations associated with the hypertensive state in the SHR. Finally, Western blot analysis of L-type Ca2+ channel (α1C) protein levels in renal resistance arterioles of the untreated SHR showed no significant difference when compared with control. These results demonstrated that virally mediated delivery of AT1R-AS not only attenuates the development of hypertension on a long-term basis but prevents changes in renal vascular Ca2+ homeostasis associated with the diseases.Past Recipients of the Goldblatt Award1998 Edward W. Inscho, PhD 1997 Kristof Graf, MD Sandra Pfister, PhD 1996 Ryuichi Morishita, MD, PhD 1995 Dewan S.A. Majid, MD, PhD 1994 R. Davis Manning, Jr, PhD 1993 William J. Stekiel, PhD 1992 Albert P. Rocchini, MD 1991 Donald W. Ducharme, PhD Douglas W. Harris, MD James H. Ludens, MD Frederic Mandel, MD W. Rodney Mathews, MD 1990 Pavel Hamet, MD, PhD 1989 John M. Hamlyn, PhD 1988 Albert J. Nasjletti, MD 1987 Victor J. Dzau, MD 1986 Willa A. Hseuh, MD 1985 Daniel T. O’Connor, MD 1984 John E. Hall, PhD 1983 Gaetan Thibault, PhD 1982 Gunner Gothberg, MD 1981 Michael J. Antonaccio, PhD 1980 Donald D. Heistad, MD 1979 Carlos Ferrario, MDArthur C. Corcoran Memorial Lecturer 1999Norman K. Hollenberg, MD, PhD, is a Professor of Medicine and Radiology and Director of Research in Radiology at the Brigham and Women’s Hospital and Harvard Medical School in Boston. He is a graduate of the University of Manitoba, college of Medicine. His Doctorate in Pharmacology was obtained under the aegis of Professor Börje Uvnäs at the Karolinska Institute in Stockholm and Professor Mark Nickerson of the University of Manitoba and McGill University in Canada. His clinical training was obtained in Maitoba and at the Peter Bent Brigham Hospital in Boston under the tutelage of John Merrell, MD, one of the founders of modern nephrology. These three men had an enormous influence on his approach to biology and medicine, his value system, and his dedication to academic pursuits.One of the joys of being at Harvard Medical School and the Brigham has been the draw that this institution has been to a series of gifted, highly motivated, and hard-working research fellows. Over the past three decades, Dr Hollenberg has had more than sixty research fellows, many of whom have become professors and leaders in their community around the world.Dr Hollenberg’s research interests have included, and continue to include, the control of renal perfusion and function, sodium homeostasis, the renin-angiotensin system, the kidney in diabetes mellitus and other forms of nephropathy, pathways for Ang II generation at the tissue level, and the genes governing these processes. One outcome of that research effort has been the modulator, which is at least in part genetically determined. This research effort has been shared in a unique collaboration that now covers almost thirty years with Dr Gordon Williams, also at the Brigham. Dr Hollenberg freely shares the opinion that much of the productivity and much of the fun in the research has come from that collaboration.Beyond the research, Dr Hollenberg has had a special interest in medical publication. He served as one of four Associate Editors at the New England Journal of Medicine for seventeen years and spent an additional six years on the journal’s Editorial Board. He has also served on the editorial boards of a dozen journals. Currently, Dr Hollenberg is Editor of the Atlas of Hypertension, which will soon appear in its third edition. He is also Editor-In-Chief of a new journal, Current Hypertension Reports, which is enjoying a promising first year.Among the awards and honors that he has received, Dr Hollenberg values especially the Royal College of Physicians Gold Medal and Prize and the Medical Writers Association of the American Medal and Prize for the best medical book of the year, Heart Facts, published in 1989 and coauthored with his daughter.Past Arthur C. Corcoran Memorial Lecture Recipients1998 Suzanne Oparil, MD 1997 Alberto Nasjletti, MD 1996 Edward D. Frohlich, MD 1995 Masashi Yanigisawa, MD, PhD 1994 Salvador Moncada, MD, PhD 1993 Haralambos Gavras, MD 1992 Stevo Julius, MD 1991 Detlev Ganten, MD 1990 Hugh E. deWardener, MD 1989 Aram V. Chobanian, MD 1988 Harriet P. Dustan, MD 1987 Edgar Haber, MD 1986 Robert J. Lefkowitz, MD 1985 Robert C. Tarazi, MD 1984 Wai Yiu Cheung, PhD 1983 Michael S. Brown, MD Joseph L. Goldstein, MD 1982 Pierre L. Corvol, MD 1981 Bengt Samuelsson, MD 1980 Frederic Bartter, MD 1979 E. Eric Muirhead, MD 1978 J. Ian S. Robertson 1977 Borgie Johansson, MDMerck New Investigator Award 1999The purpose of the Merck New Investigator Award is to encourage young investigators to undertake or continue hypertension research and participate in the conference. The award permits a young investigator to travel to the annual meeting and to present research orally or in poster format and to engage in discussion with senior investigators. The candidates are young investigators (MD or PhD), fellows in training, and academicians who hold an academic rank no higher than that of instructor at the time of submission of an abstract. Each awardee (up to 10) receives $1000.The Merck New Investigator Award/Latin America is presented with the same criteria to up to five qualified new investigators who plan to pursue their careers in Latin America. Each awardee receives $2000.New Fellows, Council for High Blood Pressure 1999FellowsRajiv Agarwall, MD Motokuni Aokim, MD Hiroshi Arai, MD Michael Bader, PhD Nancy J. Brown, MD Mark C. Chappell, PhD Robin A. Felder, PhD Naomi D.L. Fisher, MD Cheryl M. Heesch, PhD Robert A. Johnson, PhD Cheryl Laffer, MD, PhD Masashi Mukoyama, MD Yoshihiro Ogawa, MD Kailash N. Pandey, PhD Yoshihiko Saito, MD Ronald D. Smith, MD, FACP Sandra Joan Taler, MD Naohisa Tamura, MD Neal L. Weintraub, MD Masadhi Yanagisawa, MD, PhD Kenichi Yasunari, MDInternational FellowsE. Marelyn Wintour-Coghlan, BSc, MSc, PhD, DSc Patrice Delafontaine, MD Carlene A. Hamilton, BSc, PhD Antonius Rabelink, MD, PhD Graham Alexander MacGregor, MA, FRCP Download figureDownload PowerPoint Figure 1. David S. Geller, MD, PhDDownload figureDownload PowerPoint Figure 2. Myron H. WeinbergerDownload figureDownload PowerPoint Figure 3. Richard P. Lifton, MD, PhD, and John E. Hall (Chair)Download figureDownload PowerPoint Figure 4. Craig C. Gelband, PhDDownload figureDownload PowerPoint Figure 5. Norman K. Hollenberg, MD, PhDDownload figureDownload PowerPoint Figure 6. Seated left to right: Maristela M. Okamoto, Andreia C. Alzamora, Celia A. Kanashiro, Barbara T. Alexander; standing left to right: Albert Nasjletti (Vice Chair), John Hall (Chair), Larry Windland (Merck), Mubarack M. Muthalif, Alexandre Alves de Silva, Patrick L. Sinn, Scott H. Carlson, Marcos E. Alfie, and Robert D. Vinson (Merck). Not present: Craig J. Hanke, Thu H. Le, and Angela K. Loihl Previous Back to top Next FiguresReferencesRelatedDetails January 2000Vol 35, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/01.HYP.35.1.524 Originally publishedJanuary 1, 2000 PDF download Advertisement